君實生物-B(01877.HK)科創板上市申請審核狀態為“已問詢”
格隆匯3月19日丨君實生物-B(01877.HK)公告,2020年3月6日,公司收到了上交所出具的上證科審(審核)[2020]72號《關於上海君實生物醫藥科技股份有限公司首次公開發行股票並在科創板上市的審核中心意見落實函》,公司對審核中心意見落實函的回覆已於2020年3月19日於上交所公開披露;2020年3月19日,上交所發佈了《科創板上市委2020年第7次審議會議公告》,上交所科創板股票上市委員會定於2020年3月30日召開2020年第7次上市委員會審議會議,審議公司在科創板股票上市事項。
目前,公司首次公開發行股票並在科創板上市申請的審核狀態為“已問詢”。公司將根據相關事項進展情況嚴格按照法律法規的規定和要求,及時履行信息披露義務,敬請廣大投資者關注,並注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.